EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions

Wei-Ven Tee, Sylvester J M Lim, Igor N Berezovsky iD

Journal of Medicinal Chemistry · 10.10.2024 · 67 (19) · 17191-17206

DOI: 10.1021/acs.jmedchem.4c01043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 26.09.2024. Verfasst von Wei-Ven Tee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, #07-01, Matrix, Singapore 138671, Singapore. Hauptthemen laut MEDLINE: Drug Design, Allosteric Site. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agency for Science, Technology and Research, Ministry of Health -Singapore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While the therapeutic potential of allosteric drugs is increasingly realized, the discovery of effectors is largely incidental. The rational design of allosteric effectors requires new state-of-the-art approaches to account for the distinct characteristics of allosteric ligands and their modes of action. We present a broadly applicable computational framework for obtaining allosteric site-effector pairs, providing targeted, highly specific, and tunable regulation to any functional site. We validated the framework using the main protease from SARS-CoV-2 and the K-RasG12D oncoprotein. High-throughput per-residue quantification of the energetics of allosteric signaling and effector binding revealed known drugs capable of inducing the required modulation upon binding. Starting from fragments of known well-characterized drugs, allosteric effectors and binding sites were designed and optimized simultaneously to achieve targeted and specific signaling to distinct functional sites, such as, for example, the switch regions of K-RasG12D. The generic framework proposed in this work will be instrumental in developing allosteric therapies aligned with a precision medicine approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignAllosteric SiteAllosteric RegulationHumansLigandsSARS-CoV-2Proto-Oncogene Proteins p21(ras)Binding Sites

Substanzen

LigandsProto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, #07-01, Matrix, Singapore 138671, Singapore.
  • Department of Biological Sciences (DBS), National University of Singapore (NUS), 8 Medical Drive, Singapore 117579, Singapore.

ORCID-Profile: Igor N Berezovsky

Förderung

  • Agency for Science, Technology and Research
  • Ministry of Health -Singapore

Zitieren

APA

Tee, W. V., Lim, S. J. M., & Berezovsky, I. N. (2024). Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions. Journal of Medicinal Chemistry, 67(19), 17191-17206. https://doi.org/10.1021/acs.jmedchem.4c01043

Vancouver

Tee WV, Lim SJM, Berezovsky IN. Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions. Journal of Medicinal Chemistry. 2024;67(19):17191-17206. doi:10.1021/acs.jmedchem.4c01043

BibTeX
@article{Tee2024,
  author = {Tee, Wei-Ven and Lim, Sylvester J M and Berezovsky, Igor N},
  title = {Toward the Design of Allosteric Effectors: Gaining Comprehensive Control of Drug Properties and Actions},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {19},
  pages = {17191--17206},
  doi = {10.1021/acs.jmedchem.4c01043}
}
Kostenlos starten →